July 16, 2010 – A new extracellular matrix (ECM) biomaterial device recently received a CE mark, meaning it can now be marketed in European Union countries. The CorMatrix ECM for Cardiac Tissue Repair from CorMatrix Cardiovascular harnesses the body’s innate ability to repair damaged cardiovascular tissue.

July 15, 2010 -- W. L. Gore and Associates recently announced that it has received the European CE mark approval for the 25 cm Gore Viabahn Endoprosthesis with Propaten Bioactive Surface. The Gore device is the longest length stent-graft available, designed to cover more of the lesion in the superficial femoral artery (SFA) potentially reducing the need for multiple devices.

July 14, 2010 – The Cedars-Sinai Heart Institute has been awarded a $1.66 million, four-year grant from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) to develop a measurement system that could help doctors predict which patients could be struck by sudden cardiac arrest, a heart rhythm disturbance that causes instant death in more than 95 percent of cases

July 14, 2010 – A Belgian biotechnology company recently announced positive safety data and preliminary efficacy results from a clinical trial of its new stem cell therapy for heart failure.

July 13, 2010 – AstraZeneca recently announced that the U.S. District Court has found that the substance patent protecting Crestor is valid and enforceable. In its ruling, the court found that no inequitable conduct was committed by any Shionogi employee. The court also held the '314 patent to be non-obvious and properly reissued.

July 12, 2010 – AngioDynamics announced today the global expansion of its Smart Port CT family of power-injectable ports, featuring its patented Vortex port technology, to include low-profile and mini models for repeated treatments such as chemotherapy and for use with computed tomography (CT).

July 12, 2010 – Lantheus Medical Imaging Inc. today announced that it has acquired the balance of the worldwide rights for gadofosveset trisodium, a unique, injectable magnetic resonance angiography (MRA) blood pool imaging agent that it currently markets in the United States as Ablavar.

July 9, 2010 – Lantheus Medical Imaging Inc. announced this week that it has signed a new manufacturing and supply agreement with MDS Nordion to purchase molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m).